Levonorgestrel intrauterine ultra low-dose - Bayer HealthCare Pharmaceuticals

Drug Profile

Levonorgestrel intrauterine ultra low-dose - Bayer HealthCare Pharmaceuticals

Alternative Names: BAY 86-5028; Fleree; G04209C; Jaydess; LCS (ULD LNG); LCS - Bayer; LCS G04209B; LCS12; LCS16; Levonorgestrel contraceptive intrauterine systems - Bayer; Levonorgestrel ultra low-dose IUD; Levonorgestrel ultra low-dose IUS; LNG-IUS; LNS ultra low-dose IUD; LNS ultra low-dose IUS; Skyla; Ultra low-dose levonorgestrel intrauterine - Bayer; Ultra low-dose LNG intrauterine - Bayer

Latest Information Update: 28 Nov 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Hormonal replacements; Norpregnanes; Oral contraceptives; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pregnancy

Most Recent Events

  • 20 Nov 2015 Adverse events data from a phase III trial in Contraception released by Bayer
  • 01 May 2015 Bayer completes a phase III trial in Contraception (In adolescents) in Austria, Belgium, Denmark, Finland, Germany, Netherlands, Sweden and Norway (NCT01434160)
  • 19 Apr 2015 Levonorgestrel intrauterine ultra low-dose (13.5mg) is still in a phase III trial for Contraception (in adolescents) in Austria, Belgium, Denmark, Finland, Germany, Netherlands, Sweden and Norway
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top